Focus on Diabetes Care

Back to articles

Glitazones: Is There Any Difference in Hepatic Toxicity?

KEY POINT

Following reports of two patients who experienced hepatic failure while taking rosiglitazone (Avandia— SmithKline Beecham), practitioners are considering more frequent hepatic monitoring than in the schedule recommended by FDA for newer thiazolidinediones.

SOURCES

Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118–21.

Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med. 2000;132:121–4. 

Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure [letter from SmithKline Beecham]. Ann Intern Med. 2000;132:164.

Otto A. Insulin resistance: new target to prevent type 2 diabetes? Pharm Today. 1999(Nov);5(11):1,15.

Otto A. Understanding insulin resistance: what in the world is PPAR? Pharm Today. 1999(Nov);5(11):14. 

Hussar D. Selected characteristics of thiazolidinedione antidiabetic agents. Pharm Today. 1999(Nov);5(11):14.